Despite the intracellular location of this oncogenic fusion protein, it has been shown that peptides derived from its junctional region can be recognized by human T cells obtained from patients with CML or normal donors and can elicit a BCR-ABL peptide-specific T cell immune response. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.